title: Nexilin, a cardiomyopathy-associated F-actin binding protein, binds and regulates IRS1 signaling in skeletal muscle cells.
abstract: Insulin stimulates glucose uptake through a highly organized and complex process that involves movement of the glucose transporter 4 (GLUT4) from intracellular storage sites to the plasma membrane. Previous studies in L6 skeletal muscle cells have shown that insulin-induced activation and assembly of insulin receptor substrate 1 (IRS1) and p85α the regulatory subunit of the Type 1A phosphatidylinositol-3-kinase (PI3K), within remodeled actin-rich membrane structures is critical for downstream signalling mediating the translocation of GLUT4. The mechanism for localization within actin cytoskeletal scaffolds is not known, as direct interaction of IRS1 or p85α with F-actin has not been demonstrated. Here we show that nexilin, a F-actin binding protein implicated in the pathogenesis of familial dilated cardiomyopathies, preferentially binds to IRS1 over IRS2 to influence glucose transport in skeletal muscle cells. Nexilin stably associates with IRS1 under basal conditions in L6 myotubes and this complex is disassembled by insulin. Exposure of L6 myotubes to Latrunculin B disrupts the spatial patterning of nexilin and its transient association with IRS1. Functional silencing of nexilin has no effect on insulin-stimulated IRS1 tyrosine phosphorylation, however it enhances recruitment of p85α to IRS1 resulting in increased PI-3, 4, 5-P(3) formation, coincident with enhanced AKT activation and glucose uptake. By contrast, overexpression of nexilin inhibits transmission of IRS1 signals to AKT. Based on these findings we propose that nexilin may tether IRS1 to actin-rich structures under basal conditions, confining IRS1 signaling to specific subcellular locations in the cell. Insulin-elicited release of this constraint may enhance the efficiency of IRS1/PI3K interaction and PI-3, 4, 5-P(3) production at localized sites. Moreover, the selective binding of nexilin to IRS1 and not IRS2 may contribute to the differential specificity of IRS isoforms in the modulation of GLUT4 trafficking in skeletal muscle cells.
authors: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors: Andrew
authors: A
authors: Lee
authors: Fumihiko
authors: F
authors: Hakuno
authors: Paul
authors: P
authors: Northcott
authors: Jeffrey E
authors: JE
authors: Pessin
authors: Maria
authors: M
authors: Rozakis Adcock
mesh_terms: D041721:3T3-L1 Cells; D000199:Actins / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D015870:Gene Expression; D020868:Gene Silencing; D005947:Glucose / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology; D055504:Insulin Receptor Substrate Proteins / Q000378:metabolism*; D051379:Mice; D008840:Microfilament Proteins / Q000235:genetics / Q000378:metabolism*; D032342:Muscle Cells / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000166:cytology / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D021381:Protein Transport; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000199:Actins; D005947:Glucose; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D008840:Microfilament Proteins; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; C116313:Nexn protein, rat
references: J Clin Invest. 2010 May;120(5):1506-14
references: 20407209
references: Mol Cell Biol. 2000 Sep;20(18):6849-59
references: 10958681
references: J Biol Chem. 2005 May 6;280(18):17978-85
references: 15738003
references: J Cell Sci. 2011 Dec 15;124(Pt 24):4147-59
references: 22247191
references: J Biol Chem. 2000 Dec 8;275(49):38151-9
references: 10950952
references: J Cell Sci. 2000 Jan;113 Pt 2:279-90
references: 10633079
references: Mol Cell Biol. 1996 Jun;16(6):3074-84
references: 8649419
references: Am J Hum Genet. 2010 Nov 12;87(5):687-93
references: 20970104
references: Trends Endocrinol Metab. 2011 Mar;22(3):110-6
references: 21216617
references: Nat Med. 2009 Nov;15(11):1281-8
references: 19881492
references: J Biol Chem. 2011 Sep 2;286(35):30837-30846
references: 21757757
references: Mol Cell Biol. 2003 Jul;23(13):4611-26
references: 12808101
references: J Biol Chem. 2003 Apr 25;278(17):14599-602
references: 12637568
references: J Biol Chem. 2000 Feb 11;275(6):3819-26
references: 10660532
references: J Biol Chem. 1995 Apr 28;270(17):10199-203
references: 7730324
references: J Biol Chem. 2005 May 13;280(19):19426-35
references: 15764603
references: Biochem Soc Trans. 2005 Apr;33(Pt 2):354-7
references: 15787605
references: Trends Endocrinol Metab. 2006 Mar;17(2):72-8
references: 16458527
references: J Biol Chem. 1999 Jul 23;274(30):20791-5
references: 10409618
references: Biochem J. 1999 Dec 1;344 Pt 2:511-8
references: 10567235
references: J Biol Chem. 2001 Apr 6;276(14):10677-82
references: 11145966
references: J Biol Chem. 2001 Dec 28;276(52):49331-6
references: 11606595
references: Biochem J. 2000 Mar 1;346 Pt 2:321-8
references: 10677349
references: J Biol Chem. 1998 Nov 6;273(45):29686-92
references: 9792680
references: J Cell Biol. 1998 Mar 9;140(5):1211-25
references: 9490733
references: J Biol Chem. 2001 Nov 9;276(45):42436-44
references: 11546823
references: Mol Biol Cell. 2002 Jul;13(7):2334-46
references: 12134073
references: J Biol Chem. 1994 Nov 25;269(47):29934-42
references: 7961991
references: Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H787-96
references: 16565309
references: J Biol Chem. 2011 Mar 25;286(12):9897-904
references: 21257757
references: J Biol Chem. 1998 May 8;273(19):11548-55
references: 9565570
references: J Clin Invest. 2001 Aug;108(3):371-81
references: 11489930
references: Cell Signal. 2011 Oct;23(10):1546-54
references: 21683139